Catherine Veen - Challenger General Growth
| CGF Stock | 6.09 0.03 0.50% |
Executive
Catherine Veen is General Growth of Challenger
| Address | Level 2, Sydney, NSW, Australia, 2000 |
| Phone | 61 2 9994 7000 |
| Web | https://www.challenger.com.au |
Challenger Management Efficiency
The company has return on total asset (ROA) of 0.0316 % which means that it generated a profit of $0.0316 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0345 %, meaning that it generated $0.0345 on every $100 dollars invested by stockholders. Challenger's management efficiency ratios could be used to measure how well Challenger manages its routine affairs as well as how well it operates its assets and liabilities. Total Current Liabilities is likely to drop to about 5.5 B in 2024. Liabilities And Stockholders Equity is likely to drop to about 24.8 B in 2024Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Thomas Jarrett | Recce | N/A | |
| BBus ACA | Iodm | 54 | |
| Rick FCA | Regis Healthcare | N/A | |
| Chris Ward | Iodm | N/A | |
| Graham Smith | Iodm | N/A | |
| Carolyn Noumertzis | Regis Healthcare | N/A | |
| Jodie Haydon | Regis Healthcare | N/A | |
| BA BCom | Recce | N/A | |
| James Burke | Iodm | N/A | |
| Maggie Niewidok | Recce | N/A | |
| Michael Horwood | Regis Healthcare | N/A | |
| Arthur Kollaras | Recce | N/A | |
| John Prendergast | Recce | 70 | |
| Michelle Baker | Regis Healthcare | N/A | |
| AGIA BBus | Regis Healthcare | N/A | |
| Damian Arena | Iodm | N/A | |
| Alex Wilkinson | Iodm | N/A | |
| Justin Reynolds | Recce | N/A | |
| Yuval Cohen | Audio Pixels Holdings | N/A | |
| Imtiaz Bhayat | Regis Healthcare | N/A | |
Management Performance
| Return On Equity | 0.0345 | ||||
| Return On Asset | 0.0316 |
Challenger Leadership Team
Elected by the shareholders, the Challenger's board of directors comprises two types of representatives: Challenger inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Challenger. The board's role is to monitor Challenger's management team and ensure that shareholders' interests are well served. Challenger's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Challenger's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Matthews, Company Secretary | ||
| Kate Ingwersen, Chief Technology | ||
| Jeremy Cooper, Chairman Income | ||
| Mark Chen, General Relations | ||
| Jane Keeley, Head Communications | ||
| Paul Marriage, Acting Advocacy | ||
| Debbie Jensen, General Marketing | ||
| Rhiannon Hornsey, Head Sustainability | ||
| Catherine Veen, General Growth | ||
| Nicolas Hamilton, CEO MD | ||
| Mandy Mannix, Chief Customer | ||
| Peter Schliebs, Chief Life | ||
| Michael Vardanega, Head Transition | ||
| Stuart Kingham, Chief Officer | ||
| BBuild AMP, Head Property | ||
| Christopher Plater, Deputy Officer | ||
| Alexandra Bell, Chief Officer | ||
| Louise Roche, Chief Officer | ||
| Anton Kapel, Actuary Solutions | ||
| Pauline BlightJohnston, Director Strategy | ||
| Victor CPA, Chief Management |
Challenger Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Challenger a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0345 | ||||
| Return On Asset | 0.0316 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.56 % | ||||
| Current Valuation | (19.21 B) | ||||
| Shares Outstanding | 691.4 M | ||||
| Shares Owned By Insiders | 23.82 % | ||||
| Shares Owned By Institutions | 26.80 % | ||||
| Price To Book | 1.08 X | ||||
| Price To Sales | 1.29 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Challenger Stock Analysis
When running Challenger's price analysis, check to measure Challenger's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Challenger is operating at the current time. Most of Challenger's value examination focuses on studying past and present price action to predict the probability of Challenger's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Challenger's price. Additionally, you may evaluate how the addition of Challenger to your portfolios can decrease your overall portfolio volatility.